Market price of Elotuzumab single box

Elotuzumab (Elotuzumab) is a targeted immune drug that has attracted much attention in the field of Multiple Myeloma in recent years. Its core value lies in its ability to synergistically activate the patient's own immune system by targeting specific cell surface receptors and improve treatment intensity from different dimensions. Therefore, it has become one of the standard combination regimens for some relapsed or refractory multiple myeloma in international guidelines. Its innovative significance lies in the fact that it has both the immunomodulatory properties of biological agents and the selectivity of targeted drugs, making it a unique supplementary effect in patients who have failed previous multi-drug treatments.

The benefits of evolizumab are mainly reflected in the additive effect of combination therapy. It does not exert its greatest efficacy as a single drug, but when combined with immunomodulators and glucocorticoids, it can bring about a more stable therapeutic response. Overseas studies have observed that when evolizumab is combined with commonly used drugs such as lenalidomide and pomalidomide, the activity of immune cells shows a significantly enhanced trend, and the disease control performance is more durable during the treatment cycle, making it an important choice for many patients who can continue to obtain benefits after undergoing traditional regimens.

Regarding price, since evolizumab has not yet been officially launched in mainland China, it cannot be purchased directly from hospitals in China, nor can it be included in the scope of medical insurance reimbursement. In overseas markets, currently only the European version of the original drug is in commercial supply, and there are no generic versions on the market. According to public market information, the price of a single box of 300mg is approximately RMB 15,000. However, due to global supply chains, regional differences and real-time exchange rate fluctuations, the price will vary to a certain extent. Generally speaking, biologics have high production costs and strict storage and transportation conditions, so there is limited room for price reduction in the short term. Whether it will enter the country in the future and whether there is the possibility of medical insurance negotiations still need to be further observed based on the listing progress and corporate strategies.

References: https://www.empliciti.com/